Saturday 17 October 2026
Export PLUR’s income statement to Excel — free account
Pluri Inc.
PLUR Healthcare Biotechnology
Pluri Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.0 million, down 24.0% from fiscal 2025. In the quarter to June 2026, revenue fell 15.8%, EPS grew 48.0%, free cash flow grew 25.0% and total debt rose 3.43%, each against the same quarter a year earlier.
0.93
0.01
−1.06%
Follow PLUR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
1 | 3 | 3 | 3 |
+8 more TTM periods Free account |
| 260.35% | 408.10% | 430.96% | 789.88% | ||
| (74.95%) | (80.48%) | (85.06%) | (65.26%) | ||
ROIC |
(526.92%) | (306.99%) | (252.28%) | (227.46%) | |
Return on Tangible Assets |
106.23% | 128.53% | 155.40% | 167.35% | |
Average Days of Receivables |
31.25 | 33.49 | 46.07 | 80.93 | |
Free Cash Flow per Share |
(2.07) | (2.16) | (2.38) | (2.35) | |
Free Cash Flow |
(20.20) | (21.69) | (22.01) | (21.10) | |
Capital Expenditures |
(0.61) | (1.33) | (1.86) | (1.53) | |
| Other line items | |||||
Cash ROIC |
(108.48%) | (88.92%) | (69.72%) | (56.45%) | |
Accounts Receivable Turnover |
6.29 | 7.79 | 8.67 | 8.09 | |
Accounts Payable Turnover |
0.25 | 0.29 | 0.34 | 0.34 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
1,546.23 | 1,261.18 | 1,122.55 | 1,057.39 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,485.43% | 1,456.26% | 1,104.85% | 1,047.74% | |
Selling, General and Administrative Expense of Revenue |
1,013.68% | 997.59% | 793.65% | 754.45% | |
Share Based Compensation of Revenue |
366.73% | 378.87% | 257.06% | 221.34% | |
Interest Coverage |
(26.76) | (27.97) | (27.49) | (26.36) | |
Operating CF/Net income |
0.82 | 0.80 | 0.77 | 0.87 | |
Depreciation/Fixed assets |
0.33 | 0.30 | 0.26 | 0.22 | |
Capex/Depreciation |
(1.20) | (2.67) | (4.21) | (4.01) | |
Revenue per Share |
0.10 | 0.11 | 0.14 | 0.15 | |
Operating CF per Share |
(2.01) | (2.02) | (2.18) | (2.18) | |
Capex per Share |
(0.06) | (0.13) | (0.20) | (0.17) | |
Capex to Sales |
0.61 | 1.23 | 1.39 | 1.15 |
Columns are period end dates